Calcium/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
II	I-protein
downregulates	O
both	O
calcineurin	O
and	O
protein	O
kinase	O
C-mediated	O
pathways	O
for	O
cytokine	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Engagement	O
of	O
the	O
T	B-protein
cell	I-protein
receptor	I-protein
for	O
antigen	O
activates	O
phospholipase	B-protein
C	I-protein
resulting	O
in	O
an	O
increase	O
in	O
intracellular	O
free	O
calcium	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
and	O
activation	O
of	O
protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
.	O

Increased	O
[	O
Ca2+	O
]	O
i	O
activates	O
Ca2+/calmodulin-dependent	B-protein
kinases	I-protein
including	O
the	O
multifunctional	O
Ca2+/calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
II	I-protein
(	O
CaM-K	B-protein
II	I-protein
)	O
,	O
as	O
well	O
as	O
calcineurin	B-protein
,	O
a	O
type	B-protein
2B	I-protein
protein	I-protein
phosphatase	I-protein
.	O

Recent	O
studies	O
have	O
identified	O
calcineurin	B-protein
as	O
a	O
key	O
enzyme	O
for	O
interleukin	O
(	O
IL	O
)	O
-2	O
and	O
IL-4	O
promoter	O
activation	O
.	O

However	O
,	O
the	O
role	O
of	O
CaM-K	B-protein
II	I-protein
remains	O
unknown	O
.	O

We	O
have	O
used	O
mutants	O
of	O
these	O
kinases	B-protein
and	O
phosphatases	B-protein
(	O
gamma	B-protein
B*CaM-K	I-protein
and	O
delta	B-protein
CaM-AI	I-protein
,	O
respectively	O
)	O
to	O
explore	O
their	O
relative	O
role	O
in	O
cytokine	B-DNA
gene	I-DNA
transcription	O
and	O
their	O
interactions	O
with	O
PKC	B-protein
-dependent	O
signaling	O
systems	O
.	O

gamma	B-protein
B*CaM-K	I-protein
and	O
delta	B-protein
CaM-AI	I-protein
,	O
known	O
to	O
exhibit	O
constitutive	O
Ca	O
(	O
2+	O
)	O
-independent	O
activity	O
,	O
were	O
cotransfected	O
(	O
alone	O
or	O
in	O
combination	O
)	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
with	O
a	O
plasmid	O
containing	O
the	O
intact	O
IL-2	B-DNA
promoter	I-DNA
driving	O
the	O
expression	O
of	O
the	O
chloramphenicol	B-DNA
acetyltransferase	I-DNA
reporter	I-DNA
gene	I-DNA
.	O

Cotransfection	O
of	O
gamma	B-protein
B*CaM-K	I-protein
with	O
the	O
IL-2	B-DNA
promoter	I-DNA
construct	I-DNA
downregulated	O
its	O
transcription	O
in	O
response	O
to	O
stimulation	O
with	O
ionomycin	O
and	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

The	O
inhibitory	O
effect	O
of	O
CaM-K	B-protein
II	I-protein
on	O
IL-2	B-DNA
promoter	I-DNA
was	O
associated	O
with	O
decreased	O
transcription	O
of	O
its	O
AP-1	O
and	O
NF-AT	O
transactivating	O
pathways	O
.	O

Under	O
the	O
same	O
conditions	O
,	O
delta	B-protein
CaM-AI	I-protein
superinduced	O
IL-2	B-DNA
promoter	I-DNA
activity	O
(	O
approximately	O
twofold	O
increase	O
)	O
.	O

When	O
both	O
mutants	O
were	O
used	O
in	O
combination	O
,	O
gamma	B-protein
B*CaM-K	I-protein
inhibited	O
the	O
induction	O
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
by	O
delta	B-protein
CaM-AI	I-protein
.	O

Similar	O
results	O
were	O
obtained	O
when	O
a	O
construct	O
containing	O
the	O
IL-4	B-DNA
promoter	I-DNA
also	O
was	O
used	O
.	O

gamma	B-protein
B*CaM-K	I-protein
also	O
downregulated	O
the	O
activation	O
of	O
AP-1	B-protein
in	O
response	O
to	O
transfection	O
with	O
a	O
constitutively	O
active	O
mutant	O
of	O
PKC	B-protein
or	O
stimulation	O
with	O
PMA	O
.	O

These	O
results	O
suggest	O
that	O
CaM-K	B-protein
II	I-protein
may	O
exert	O
negative	O
influences	O
on	O
cytokine	B-DNA
gene	I-DNA
transcription	O
in	O
human	B-cell_type
T	I-cell_type
cells	I-cell_type
,	O
and	O
provide	O
preliminary	O
evidence	O
for	O
negative	O
cross-talk	O
with	O
the	O
calcineurin-	O
and	O
PKC-	O
dependent	O
signaling	O
systems	O
.	O

Brief	NULL
Definitive	NULL
Report	NULL
Calcium	NULL
/Calmodulin-dependent	NULL
Protein	NULL
Kinase	NULL
II	NULL
Downregulates	NULL
Both	NULL
Calcineurin	NULL
and	NULL
Protein	NULL
Kinase	NULL
C-mediated	NULL
Pathways	NULL
for	NULL
Cytokine	NULL
Gene	NULL
Transcription	NULL
in	NULL
Human	NULL
T	NULL
Cells	NULL
By	NULL
Nobuaki	NULL
Hama	NULL
,	NULL
Fotini	NULL
Paliogianni	NULL
,	NULL
Barri	NULL
J.	NULL
Fessler	NULL
,	NULL
and	NULL
Dimitrios	NULL
T.	NULL
Boumpas	NULL
From	NULL
the	NULL
Kidney	NULL
Disease	NULL
Section	NULL
,	NULL
Metabolic	NULL
Diseases	NULL
Branch	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Diabetes	NULL
and	NULL
Digestive	NULL
and	NULL
Kidney	NULL
Diseases	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892	NULL
Summary	NULL
Engagement	NULL
of	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
for	NULL
antigen	NULL
activates	NULL
phospholipase	NULL
C	NULL
resulting	NULL
in	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
free	NULL
calcium	NULL
concentration	NULL
(	NULL
[	NULL
Ca	NULL
#	NULL
+	NULL
]	NULL
;	NULL
)	NULL
and	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
.	NULL

Increased	NULL
[	NULL
Ca	NULL
#	NULL
*	NULL
]	NULL
;	NULL
activates	NULL
Ca**/calmodulin-dependent	NULL
kinases	NULL
including	NULL
the	NULL
multifunctional	NULL
Ca**/calmodulin-dependent	NULL
protein	NULL
kinase	NULL
II	NULL
(	NULL
CaM-K	NULL
II	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
calcineurin	NULL
,	NULL
a	NULL
type	NULL
2B	NULL
protein	NULL
phosphatase	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
identified	NULL
calcineurin	NULL
as	NULL
a	NULL
key	NULL
enzyme	NULL
for	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-2	NULL
and	NULL
IL-4	NULL
promoter	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
the	NULL
role	NULL
of	NULL
CaM-K	NULL
II	NULL
remains	NULL
unknown	NULL
.	NULL

We	NULL
have	NULL
used	NULL
mutants	NULL
of	NULL
these	NULL
kinases	NULL
and	NULL
phosphatases	NULL
(	NULL
ys3	NULL
``	NULL
*CaM-K	NULL
and	NULL
ACaM-Al	NULL
,	NULL
respectively	NULL
)	NULL
to	NULL
explore	NULL
their	NULL
relative	NULL
role	NULL
in	NULL
cytokine	NULL
gene	NULL
transcription	NULL
and	NULL
their	NULL
interactions	NULL
with	NULL
PKC-dependent	NULL
signaling	NULL
systems	NULL
.	NULL

ys	NULL
``	NULL
CaM-K	NULL
and	NULL
ACaM-AI	NULL
,	NULL
known	NULL
to	NULL
exhibit	NULL
constitutive	NULL
Ca**-independent	NULL
activity	NULL
,	NULL
were	NULL
cotransfected	NULL
(	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
)	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
intact	NULL
IL-2	NULL
promoter	NULL
driving	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
reporter	NULL
gene	NULL
.	NULL

Cotransfection	NULL
of	NULL
ys*CaM-K	NULL
with	NULL
the	NULL
IL-2	NULL
promoter	NULL
construct	NULL
downregulated	NULL
its	NULL
transcription	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
ionomycin	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
.	NULL

The	NULL
inhibitory	NULL
effect	NULL
of	NULL
CaM-K	NULL
II	NULL
on	NULL
IL-2	NULL
promoter	NULL
was	NULL
associated	NULL
with	NULL
decreased	NULL
transcription	NULL
of	NULL
its	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
transactivating	NULL
pathways	NULL
.	NULL

Under	NULL
the	NULL
same	NULL
conditions	NULL
,	NULL
ACaM-AI	NULL
superin-duced	NULL
IL-2	NULL
promoter	NULL
activity	NULL
(	NULL
approximately	NULL
twofold	NULL
increase	NULL
)	NULL
.	NULL

When	NULL
both	NULL
mutants	NULL
were	NULL
used	NULL
in	NULL
combination	NULL
,	NULL
y3*CaM-K	NULL
inhibited	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
ACaM-AI	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
a	NULL
construct	NULL
containing	NULL
the	NULL
IL-4	NULL
promoter	NULL
also	NULL
was	NULL
used	NULL
.	NULL

y3	NULL
``	NULL
CaM-K.	NULL
also	NULL
downregulated	NULL
the	NULL
activation	NULL
of	NULL
AP-1	NULL
in	NULL
response	NULL
to	NULL
transfection	NULL
with	NULL
a	NULL
constitutively	NULL
active	NULL
mutant	NULL
of	NULL
PKC	NULL
or	NULL
stimulation	NULL
with	NULL
PMA	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
CaM-K	NULL
II	NULL
may	NULL
exert	NULL
negative	NULL
influences	NULL
on	NULL
cytokine	NULL
gene	NULL
transcription	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
,	NULL
and	NULL
provide	NULL
preliminary	NULL
evidence	NULL
for	NULL
negative	NULL
cross-talk	NULL
with	NULL
the	NULL
calcineurin-	NULL
and	NULL
PKC-dependent	NULL
signaling	NULL
systems	NULL
.	NULL

L2	NULL
gene	NULL
transcription	NULL
is	NULL
controlled	NULL
by	NULL
a	NULL
promoter	NULL
re	NULL
gion	NULL
extending	NULL
~326	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

This	NULL
promoter	NULL
region	NULL
contains	NULL
binding	NULL
sites	NULL
for	NULL
at	NULL
least	NULL
five	NULL
nuclear	NULL
proteins	NULL
including	NULL
nuclear	NULL
factors	NULL
NF-AT	NULL
,	NULL
Oct-1	NULL
,	NULL
NF-	NULL
Â«	NULL
B	NULL
,	NULL
AP-1	NULL
,	NULL
and	NULL
CD28RC	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Both	NULL
an	NULL
increase	NULL
of	NULL
cytoplasmic	NULL
calcium	NULL
(	NULL
Ca**	NULL
)	NULL
and	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
are	NULL
required	NULL
for	NULL
its	NULL
activation	NULL
in	NULL
resting	NULL
T	NULL
cells	NULL
.	NULL

Recent	NULL
studies	NULL
have	NULL
established	NULL
that	NULL
the	NULL
Ca	NULL
#	NULL
+/calmodulin-dependent	NULL
protein	NULL
kinase	NULL
II	NULL
(	NULL
CaM	NULL
kinase	NULL
II	NULL
)	NULL
is	NULL
the	NULL
general	NULL
or	NULL
multifunctional	NULL
kinase	NULL
of	NULL
Ca*+-signaling	NULL
systems	NULL
(	NULL
reviewed	NULL
in	NULL
3	NULL
)	NULL
.	NULL

CaM	NULL
kinase	NULL
II	NULL
is	NULL
present	NULL
in	NULL
most	NULL
tissues	NULL
as	NULL
an	NULL
oligomer	NULL
composed	NULL
of	NULL
6-12	NULL
subunits	NULL
,	NULL
depending	NULL
on	NULL
the	NULL
isoform	NULL
and	NULL
tissue	NULL
.	NULL

All	NULL
11	NULL
isoforms	NULL
described	NULL
to	NULL
date	NULL
(	NULL
ax	NULL
,	NULL
ss	NULL
,	NULL
B	NULL
,	NULL
B	NULL
'	NULL
,	NULL
ya	NULL
.	NULL

ys	NULL
,	NULL
Yo	NULL
,	NULL
da	NULL
,	NULL
ds	NULL
or	NULL
53	NULL
,	NULL
dc	NULL
or	NULL
82	NULL
,	NULL
5p	NULL
or	NULL
84	NULL
)	NULL
share	NULL
a	NULL
highly	NULL
conserved	NULL
catalytic	NULL
domain	NULL
at	NULL
the	NULL
NH	NULL
>	NULL
-terminal	NULL
portion	NULL
of	NULL
the	NULL
molecule	NULL
,	NULL
an	NULL
autoinhibitory	NULL
sequence	NULL
overlapping	NULL
with	NULL
a	NULL
calmodulin	NULL
binding	NULL
region	NULL
and	NULL
an	NULL
association	NULL
domain	NULL
which	NULL
1217	NULL
is	NULL
important	NULL
for	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
holoenzyme	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

After	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
free	NULL
Ca*+*	NULL
concentration	NULL
(	NULL
[	NULL
CaÂ®*	NULL
)	NULL
;	NULL
)	NULL
,	NULL
Ca	NULL
%	NULL
+	NULL
/calmodulin	NULL
activates	NULL
CaM	NULL
kinase	NULL
II	NULL
causing	NULL
the	NULL
kinase	NULL
to	NULL
phosphorylate	NULL
itself	NULL
on	NULL
the	NULL
ThrÂ®	NULL
``	NULL
(	NULL
a	NULL
isoform	NULL
)	NULL
or	NULL
Thr	NULL
``	NULL
(	NULL
B	NULL
and	NULL
y	NULL
isoforms	NULL
)	NULL
site	NULL
of	NULL
the	NULL
autoinhibitory	NULL
domain	NULL
.	NULL

This	NULL
phosphorylation	NULL
event	NULL
results	NULL
in	NULL
disruption	NULL
of	NULL
the	NULL
autoinhibitory	NULL
domain	NULL
and	NULL
Ca	NULL
#	NULL
*-independent	NULL
activity	NULL
(	NULL
~20-80	NULL
%	NULL
of	NULL
maximal	NULL
Ca	NULL
#	NULL
*-stimulated	NULL
activity	NULL
)	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Mutations	NULL
at	NULL
ThrÂ®Â®	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
change	NULL
to	NULL
Asp	NULL
)	NULL
result	NULL
in	NULL
mutants	NULL
with	NULL
20-40	NULL
%	NULL
activity	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Ca	NULL
#	NULL
+*	NULL
/calmodulin	NULL
stimulation	NULL
(	NULL
3	NULL
)	NULL
.	NULL

Constitutively	NULL
active	NULL
mutants	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
can	NULL
be	NULL
used	NULL
to	NULL
investigate	NULL
its	NULL
role	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
and	NULL
to	NULL
isolate	NULL
the	NULL
potential	NULL
effects	NULL
of	NULL
this	NULL
enzyme	NULL
from	NULL
other	NULL
Ca*-dependent	NULL
events	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Increase	NULL
in	NULL
[	NULL
Ca	NULL
#	NULL
+	NULL
]	NULL
;	NULL
and	NULL
activation	NULL
of	NULL
calmodulin	NULL
may	NULL
also	NULL
activate	NULL
Ca**/calmodulin-dependent	NULL
phosphatases	NULL
such	NULL
as	NULL
calcineurin	NULL
,	NULL
a	NULL
type	NULL
2B	NULL
serine/threonine	NULL
protein	NULL
phosphatase	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Experimental	NULL
Medicine	NULL
Â«	NULL
Volume	NULL
181	NULL
March	NULL
1995	NULL
1217-1222	NULL
Work	NULL
from	NULL
several	NULL
laboratories	NULL
has	NULL
identified	NULL
calcineurin	NULL
as	NULL
a	NULL
key	NULL
enzyme	NULL
needed	NULL
for	NULL
IL-2	NULL
and	NULL
I4	NULL
promoter	NULL
activity	NULL
(	NULL
7-9	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
its	NULL
effects	NULL
on	NULL
the	NULL
intact	NULL
IL-2	NULL
promoter	NULL
,	NULL
calcineurin	NULL
can	NULL
separately	NULL
lead	NULL
to	NULL
the	NULL
transactivation	NULL
of	NULL
nuclear	NULL
factors	NULL
NF-AT	NULL
and	NULL
Oct-1	NULL
(	NULL
NF-IL2A	NULL
,	NULL
OAP/Oct-1	NULL
)	NULL
.	NULL

More	NULL
recent	NULL
data	NULL
have	NULL
also	NULL
suggested	NULL
that	NULL
calcineurin	NULL
may	NULL
act	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
inactivate	NULL
IxB/MAD3	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
NF-KB	NULL
,	NULL
thereby	NULL
resulting	NULL
in	NULL
net	NULL
activation	NULL
of	NULL
the	NULL
NF-KB	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Whereas	NULL
the	NULL
role	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
has	NULL
been	NULL
well	NULL
defined	NULL
in	NULL
neuronal	NULL
tissues	NULL
,	NULL
its	NULL
role	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
remains	NULL
largely	NULL
unknown	NULL
.	NULL

In	NULL
human	NULL
lymphocytes	NULL
,	NULL
stimulation	NULL
via	NULL
the	NULL
TCR	NULL
or	NULL
with	NULL
calcium	NULL
ionophores	NULL
increases	NULL
CaM	NULL
kinase	NULL
II	NULL
activity	NULL
(	NULL
5	NULL
,	NULL
11	NULL
)	NULL
.	NULL

Using	NULL
constitutively	NULL
active	NULL
mutants	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
,	NULL
calcineurin	NULL
,	NULL
and	NULL
PKC	NULL
,	NULL
we	NULL
asked	NULL
whether	NULL
CaM	NULL
kinase	NULL
II	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
IL-2	NULL
and	NULL
IL-4	NULL
promoter	NULL
transcription	NULL
and	NULL
its	NULL
influence	NULL
on	NULL
the	NULL
effects	NULL
of	NULL
calcineurin-	NULL
and	NULL
PKC	NULL
-dependent	NULL
signaling	NULL
systems	NULL
.	NULL

Our	NULL
data	NULL
indicate	NULL
that	NULL
CaM	NULL
kinase	NULL
downregulates	NULL
the	NULL
transcription	NULL
of	NULL
these	NULL
cytokines	NULL
and	NULL
provides	NULL
preliminary	NULL
evidence	NULL
for	NULL
cross-talk	NULL
among	NULL
these	NULL
pathways	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Cell	NULL
Culture	NULL
-	NULL
Human	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI-1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
PCS	NULL
,	NULL
25	NULL
ug/ml	NULL
gentamicin	NULL
,	NULL
and	NULL
5	NULL
x	NULL
10-5	NULL
M	NULL
2-ME	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Plasmid	NULL
Constructs	NULL
.	NULL

-	NULL
The	NULL
reporter	NULL
plasmid	NULL
IL-2	NULL
CAT	NULL
contains	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
(	NULL
base	NULL
pairs	NULL
-448	NULL
to	NULL
+43	NULL
)	NULL
directing	NULL
the	NULL
transcription	NULL
of	NULL
the	NULL
chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
gene	NULL
.	NULL

This	NULL
plasmid	NULL
also	NULL
includes	NULL
an	NULL
SV	NULL
40	NULL
polyadenylation	NULL
site	NULL
between	NULL
vector	NULL
sequences	NULL
and	NULL
-448	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
to	NULL
prevent	NULL
vector-depen-dent	NULL
transcription	NULL
from	NULL
contributing	NULL
to	NULL
the	NULL
observed	NULL
CAT	NULL
activity	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Plasmid	NULL
AP-1	NULL
CAT	NULL
(	NULL
TRE-tk	NULL
CAT	NULL
)	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
M.	NULL
Karin	NULL
,	NULL
University	NULL
of	NULL
California	NULL
at	NULL
San	NULL
Diego	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
contains	NULL
a	NULL
synthetic	NULL
oligonucleotide	NULL
from	NULL
-73	NULL
to	NULL
-65	NULL
of	NULL
the	NULL
human	NULL
col-lagenase	NULL
gene	NULL
cloned	NULL
into	NULL
the	NULL
HindIII/BamHI	NULL
cut	NULL
of	NULL
pBLCAT	NULL
2	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
Herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
from	NULL
position	NULL
-109	NULL
to	NULL
+51	NULL
in	NULL
front	NULL
of	NULL
the	NULL
CAT	NULL
structural	NULL
gene	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Plasmid	NULL
NF-AT	NULL
CAT	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
Stanford	NULL
University	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
has	NULL
three	NULL
copies	NULL
of	NULL
NF-AT-binding	NULL
site	NULL
containing	NULL
5	NULL
'	NULL
IL-2	NULL
sequences	NULL
-255	NULL
to	NULL
~285	NULL
linked	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
sequences	NULL
from	NULL
-72	NULL
to	NULL
+47	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Plasmid	NULL
IL-4	NULL
CAT	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
G.	NULL
Thyphronitis	NULL
,	NULL
Institute	NULL
Pasteur	NULL
,	NULL
Lille	NULL
,	NULL
France	NULL
)	NULL
contains	NULL
the	NULL
human	NULL
IL-4	NULL
promoter	NULL
(	NULL
base	NULL
pairs	NULL
-418	NULL
to	NULL
+50	NULL
)	NULL
cloned	NULL
into	NULL
the	NULL
Not	NULL
I	NULL
site	NULL
of	NULL
pUMSP	NULL
;	NULL
,	NULL
,	NULL
which	NULL
is	NULL
on	NULL
a	NULL
pSVOCAT-based	NULL
vector	NULL
that	NULL
contains	NULL
the	NULL
upstream	NULL
sequences	NULL
of	NULL
the	NULL
c-mos	NULL
gene	NULL
to	NULL
stop	NULL
read-through	NULL
transcription	NULL
,	NULL
and	NULL
the	NULL
polylinker	NULL
of	NULL
the	NULL
pBluescript	NULL
.	NULL

Plasmid	NULL
ys	NULL
``	NULL
CaM-K	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
H.	NULL
Schulman	NULL
,	NULL
Stanford	NULL
University	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
is	NULL
a	NULL
constitutive	NULL
mutant	NULL
of	NULL
the	NULL
human	NULL
T	NULL
lymphocyte	NULL
y3CaM	NULL
kinase	NULL
(	NULL
5	NULL
)	NULL
.	NULL

EcoRI	NULL
linkers	NULL
were	NULL
added	NULL
to	NULL
the	NULL
Clal-NotI	NULL
fragment	NULL
containing	NULL
the	NULL
full-length	NULL
ysCaM	NULL
kinase	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
then	NULL
inserted	NULL
into	NULL
pSR	NULL
&	NULL
BKS	NULL
,	NULL
forming	NULL
a	NULL
complete	NULL
ysCaM	NULL
kinase-SRe	NULL
Â«	NULL
x	NULL
expression	NULL
construct	NULL
.	NULL

Subsequently	NULL
,	NULL
ThrÂ®*	NULL
``	NULL
was	NULL
replaced	NULL
with	NULL
Asp	NULL
using	NULL
site-directed	NULL
mutagenesis	NULL
to	NULL
make	NULL
mutant	NULL
ys	NULL
``	NULL
CaM-K	NULL
.	NULL

This	NULL
mutation	NULL
mimics	NULL
the	NULL
effect	NULL
of	NULL
autophosphorylation	NULL
on	NULL
disrupting	NULL
the	NULL
autoinhibitory	NULL
domain	NULL
and	NULL
generates	NULL
a	NULL
CaM	NULL
kinase	NULL
which	NULL
is	NULL
substantially	NULL
Ca**	NULL
-independent	NULL
.	NULL

ys	NULL
``	NULL
*CaM-K	NULL
was	NULL
nearly	NULL
40	NULL
%	NULL
active	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Ca**/calmodulin	NULL
(	NULL
5	NULL
)	NULL
.	NULL

In	NULL
cells	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
,	NULL
and	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
ys*CaM-K	NULL
,	NULL
the	NULL
activity	NULL
(	NULL
determined	NULL
in	NULL
cytoplasmic	NULL
extracts	NULL
using	NULL
the	NULL
synthetic	NULL
1218	NULL
peptide	NULL
substrate	NULL
syntide	NULL
that	NULL
is	NULL
recognized	NULL
by	NULL
this	NULL
kinase	NULL
)	NULL
was	NULL
two-to	NULL
threefold	NULL
higher	NULL
than	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
its	NULL
vector	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Plasmid	NULL
double	NULL
mutant	NULL
(	NULL
inactive/constitutive	NULL
)	NULL
yeCaM-K	NULL
(	NULL
also	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
H.	NULL
Schulman	NULL
)	NULL
is	NULL
the	NULL
catalytically	NULL
inactive	NULL
mutant	NULL
of	NULL
Double	NULL
mutant	NULL
ys	NULL
``	NULL
*CaM-K	NULL
was	NULL
constructed	NULL
by	NULL
replacing	NULL
Lys*Â®	NULL
(	NULL
which	NULL
is	NULL
a	NULL
conserved	NULL
residue	NULL
essential	NULL
for	NULL
catalytic	NULL
activity	NULL
)	NULL
with	NULL
Met	NULL
in	NULL
the	NULL
ATP	NULL
binding	NULL
(	NULL
catalytic	NULL
)	NULL
domain	NULL
.	NULL

Plasmid	NULL
ACaM-Al	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
R.	NULL
L.	NULL
Kincaid	NULL
,	NULL
Human	NULL
Genome	NULL
Sciences	NULL
,	NULL
Inc.	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
)	NULL
is	NULL
a	NULL
deletion	NULL
mutant	NULL
of	NULL
the	NULL
catalytic	NULL
subunit	NULL
of	NULL
the	NULL
wild-type	NULL
murine	NULL
calcineurin	NULL
,	NULL
the	NULL
sequence	NULL
of	NULL
which	NULL
has	NULL
99	NULL
%	NULL
homology	NULL
to	NULL
the	NULL
corresponding	NULL
human	NULL
subunit	NULL
.	NULL

ACaM-Al	NULL
lacks	NULL
functional	NULL
CaM-binding	NULL
and	NULL
autoinhibitory	NULL
domains	NULL
.	NULL

This	NULL
truncation	NULL
was	NULL
designed	NULL
to	NULL
mimic	NULL
proteolyzed	NULL
forms	NULL
of	NULL
the	NULL
phosphatase	NULL
known	NULL
to	NULL
have	NULL
-independent	NULL
,	NULL
constitutive	NULL
phosphatase	NULL
activity	NULL
in	NULL
vitro	NULL
(	NULL
7	NULL
)	NULL
.	NULL

Plasmid	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
M.-A	NULL
.	NULL

Muramatsu	NULL
,	NULL
University	NULL
of	NULL
Tokyo	NULL
,	NULL
Tokyo	NULL
,	NULL
Japan	NULL
)	NULL
is	NULL
the	NULL
constitutively	NULL
active	NULL
mutant	NULL
of	NULL
PKCB	NULL
which	NULL
lacks	NULL
the	NULL
regulatory	NULL
domain	NULL
(	NULL
phorbol	NULL
ester	NULL
binding	NULL
domain	NULL
)	NULL
.	NULL

APKCB	NULL
lacks	NULL
the	NULL
coding	NULL
region	NULL
for	NULL
amino	NULL
acids	NULL
at	NULL
positions	NULL
6-159	NULL
of	NULL
PKC	NULL
(	NULL
13	NULL
)	NULL
.	NULL

In	NULL
control	NULL
experiments	NULL
,	NULL
the	NULL
expression	NULL
vector	NULL
alone	NULL
was	NULL
used	NULL
.	NULL

DNA	NULL
Transfections	NULL
.	NULL

-	NULL
Transfections	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
were	NULL
carried	NULL
out	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
14	NULL
)	NULL
.	NULL

To	NULL
monitor	NULL
and	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
,	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
pCMV.Gal	NULL
which	NULL
contains	NULL
the	NULL
CMV-IE	NULL
promoter	NULL
directing	NULL
transcription	NULL
of	NULL
the	NULL
bacterial	NULL
B-galactosidase	NULL
(	NULL
3-gal	NULL
)	NULL
gene	NULL
(	NULL
7	NULL
)	NULL
.	NULL

CAT	NULL
Assay	NULL
.	NULL

-	NULL
The	NULL
CAT	NULL
assay	NULL
was	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
.	NULL

The	NULL
CAT	NULL
activity	NULL
was	NULL
then	NULL
normalized	NULL
to	NULL
the	NULL
B-gal	NULL
activity	NULL
.	NULL

Results	NULL
ys*CaM-K	NULL
Does	NULL
Not	NULL
Substitute	NULL
for	NULL
The	NULL
Ca**-dependent	NULL
Signaling	NULL
Pathway	NULL
for	NULL
IL-2	NULL
Promoter	NULL
Transactivation	NULL
.	NULL

-	NULL
In	NULL
the	NULL
Jurkat	NULL
model	NULL
system	NULL
,	NULL
ACaM-AI	NULL
can	NULL
substitute	NULL
for	NULL
the	NULL
CaÂ®*	NULL
signal	NULL
required	NULL
for	NULL
IL-2	NULL
gene	NULL
transcription	NULL
(	NULL
7	NULL
,	NULL
8	NULL
,	NULL
14	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
we	NULL
cotransfected	NULL
a	NULL
plasmid	NULL
containing	NULL
the	NULL
IL-2	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
along	NULL
with	NULL
plasmids	NULL
ACaM-Al	NULL
or	NULL
y3*CaM-K	NULL
into	NULL
these	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and/or	NULL
PMA	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
both	NULL
ionomycin	NULL
and	NULL
PMA	NULL
were	NULL
required	NULL
for	NULL
IL-2	NULL
promoter	NULL
activation	NULL
.	NULL

ACaM-AI	NULL
was	NULL
able	NULL
to	NULL
partially	NULL
substitute	NULL
for	NULL
the	NULL
Ca	NULL
#	NULL
*	NULL
ionophore	NULL
(	NULL
~50	NULL
%	NULL
activity	NULL
as	NULL
compared	NULL
to	NULL
stimulation	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
addition	NULL
of	NULL
ionomycin	NULL
further	NULL
induced	NULL
IL-2	NULL
promoter	NULL
activity	NULL
by	NULL
approximately	NULL
twofold	NULL
(	NULL
range	NULL
1.8-2.4	NULL
)	NULL
suggesting	NULL
that	NULL
in	NULL
addition	NULL
to	NULL
calcineurin	NULL
other	NULL
Ca**-dependent	NULL
pathways	NULL
are	NULL
also	NULL
involved	NULL
in	NULL
IL-2	NULL
promoter	NULL
activity	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
calcineurin	NULL
was	NULL
specific	NULL
since	NULL
it	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
unrelated	NULL
promoter	NULL
pCMV.Gal	NULL
(	NULL
98.9	NULL
+	NULL
15.3	NULL
%	NULL
of	NULL
activity	NULL
of	NULL
cells	NULL
treated	NULL
with	NULL
the	NULL
vector	NULL
alone	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
the	NULL
same	NULL
figure	NULL
,	NULL
these	NULL
pathways	NULL
most	NULL
likely	NULL
do	NULL
not	NULL
involve	NULL
CaM	NULL
kinase	NULL
,	NULL
since	NULL
in	NULL
similar	NULL
experiments	NULL
ys	NULL
``	NULL
CaM-K	NULL
not	NULL
only	NULL
could	NULL
not	NULL
substitute	NULL
for	NULL
ionomycin	NULL
but	NULL
,	NULL
to	NULL
the	NULL
contrary	NULL
,	NULL
exerted	NULL
a	NULL
negative	NULL
effect	NULL
on	NULL
the	NULL
transactivation	NULL
of	NULL
IL-2	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
(	NULL
see	NULL
below	NULL
)	NULL
.	NULL

ys*CaM-K	NULL
Inhibits	NULL
IL-2	NULL
Promoter	NULL
Activation	NULL
by	NULL
Down-regulating	NULL
Its	NULL
Transactivating	NULL
Pathways	NULL
AP-1	NULL
and	NULL
NFAT	NULL
.	NULL

The	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
sites	NULL
are	NULL
critical	NULL
for	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
1	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
ys*CaM-K	NULL
on	NULL
IL-2	NULL
promoter	NULL
was	NULL
CaM	NULL
Kinase	NULL
II	NULL
and	NULL
Cytokine	NULL
Gene	NULL
Transcription	NULL
IL-2	NULL
CAT	NULL
PMA	NULL
_	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
+	NULL
lon	NULL
.	NULL

-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
an	NULL
L	NULL
]	NULL
L	NULL
I	NULL
L	NULL
|	NULL
Vector	NULL
ACaM-Al	NULL
__	NULL
yf	NULL
CaM-K	NULL
Figure	NULL
1	NULL
.	NULL

-	NULL
ACaM-Al	NULL
but	NULL
not	NULL
y83	NULL
``	NULL
CaM-K	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
phorbol	NULL
esters	NULL
to	NULL
mediate	NULL
the	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
plasmid	NULL
IL-2	NULL
CAT	NULL
(	NULL
which	NULL
contains	NULL
the	NULL
IL-2	NULL
promoter	NULL
driving	NULL
the	NULL
expression	NULL
of	NULL
CAT	NULL
gene	NULL
)	NULL
alone	NULL
or	NULL
in	NULL
combi-pation	NULL
with	NULL
plasmids	NULL
ACaM-AI	NULL
or	NULL
y3	NULL
``	NULL
*CaM-K	NULL
(	NULL
10	NULL
pg	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
PMA	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
ionomycin	NULL
.	NULL

mediated	NULL
by	NULL
these	NULL
cis-acting	NULL
elements	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
constructs	NULL
containing	NULL
the	NULL
intact	NULL
ILb2	NULL
promoter	NULL
or	NULL
its	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
sites	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
.	NULL

ys	NULL
``	NULL
*CaM-K	NULL
decreased	NULL
the	NULL
activity	NULL
of	NULL
all	NULL
three	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
four	NULL
different	NULL
experiments	NULL
ys*CaM-K	NULL
decreased	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
construct	NULL
by	NULL
~50	NULL
%	NULL
(	NULL
53.4	NULL
+	NULL
9.2	NULL
)	NULL
,	NULL
of	NULL
the	NULL
AP-1	NULL
by	NULL
~70	NULL
%	NULL
(	NULL
68.5	NULL
+	NULL
3.9	NULL
)	NULL
,	NULL
and	NULL
NF-AT	NULL
by	NULL
w35	NULL
%	NULL
(	NULL
34.2	NULL
+	NULL
74	NULL
)	NULL
.	NULL

The	NULL
downregulatory	NULL
effect	NULL
of	NULL
yp	NULL
``	NULL
CaM-K.	NULL
was	NULL
specific	NULL
since	NULL
it	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
unrelated	NULL
promoter	NULL
pCMV.Gal	NULL
(	NULL
95.8	NULL
+	NULL
9.3	NULL
%	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
vector	NULL
alone	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
cotransfection	NULL
of	NULL
the	NULL
double	NULL
mutant	NULL
(	NULL
inactive/constitutive	NULL
)	NULL
ysCaM-K	NULL
did	NULL
not	NULL
downregulate	NULL
the	NULL
IL-2	NULL
promoter	NULL
IL-2	NULL
CAT	NULL
AP-1	NULL
CAT	NULL
NF-AT	NULL
CAT	NULL
x	NULL
100	NULL
y	NULL
E	NULL
2	NULL
9	NULL
<	NULL
4	NULL
t	NULL
;	NULL
50	NULL
G	NULL
LU	NULL
>	NULL
f	NULL
3	NULL
Ly	NULL
Â§	NULL
&	NULL
$	NULL
&	NULL
&	NULL
&	NULL
5	NULL
Â«	NULL
$	NULL
&	NULL
-	NULL
&	NULL
f	NULL
-Â£	NULL
,	NULL
P	NULL
y	NULL
5:5	NULL
Â«	NULL
Â®	NULL
y	NULL
Â«	NULL
Â®	NULL
Figure	NULL
2.	NULL
ya	NULL
``	NULL
*CaM-K	NULL
inhibits	NULL
IL2	NULL
promoter	NULL
activation	NULL
by	NULL
down-regulating	NULL
its	NULL
transactivating	NULL
pathways	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
.	NULL

Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
plasmids	NULL
IL-2	NULL
CAT	NULL
,	NULL
AP-1	NULL
CAT	NULL
or	NULL
NF-AT	NULL
CAT	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
and	NULL
ys	NULL
``	NULL
*CaM-K	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
or	NULL
its	NULL
vector	NULL
,	NULL
and	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
.	NULL

Results	NULL
(	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
activity	NULL
observed	NULL
when	NULL
cells	NULL
were	NULL
stimulated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
vector	NULL
)	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
activity	NULL
of	NULL
pCMV.Gal	NULL
which	NULL
was	NULL
used	NULL
to	NULL
control	NULL
for	NULL
transfection	NULL
efficiency	NULL
(	NULL
mean	NULL
+	NULL
SE	NULL
)	NULL
.	NULL

1219	NULL
Hama	NULL
et	NULL
al	NULL
.	NULL

activity	NULL
(	NULL
122.2	NULL
+	NULL
8.9	NULL
%	NULL
of	NULL
the	NULL
activity	NULL
of	NULL
cells	NULL
transfected	NULL
with	NULL
the	NULL
vector	NULL
alone	NULL
in	NULL
four	NULL
independent	NULL
experiments	NULL
)	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

ys*CaM-K	NULL
Downregulates	NULL
the	NULL
Transcription	NULL
of	NULL
Other	NULL
CaÂ®*-dependent	NULL
Promoters	NULL
.	NULL

-	NULL
In	NULL
addition	NULL
to	NULL
11-2	NULL
promoter	NULL
the	NULL
Ca	NULL
?	NULL

*	NULL
pathway	NULL
is	NULL
also	NULL
involved	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
other	NULL
cytokine	NULL
promoters	NULL
such	NULL
as	NULL
IL-4	NULL
,	NULL
a	NULL
Th2	NULL
promoter	NULL
.	NULL

Even	NULL
though	NULL
the	NULL
signal	NULL
transduction	NULL
pathway	NULL
may	NULL
be	NULL
different	NULL
in	NULL
IL-2~	NULL
and	NULL
IL-4-producing	NULL
Th1	NULL
and	NULL
Th2	NULL
clones	NULL
,	NULL
both	NULL
pathways	NULL
share	NULL
the	NULL
[	NULL
Ca	NULL
@	NULL
*	NULL
]	NULL
;	NULL
elevation	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Recent	NULL
data	NULL
have	NULL
suggested	NULL
that	NULL
calcineurin	NULL
alone	NULL
may	NULL
upregulate	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
II4	NULL
(	NULL
reference	NULL
9	NULL
and	NULL
Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
N.	NULL
Hama	NULL
,	NULL
G.	NULL
J.	NULL
Mavro-thalassitis	NULL
,	NULL
G.	NULL
Thyphronitis	NULL
,	NULL
and	NULL
D.	NULL
T.	NULL
Boumpas	NULL
,	NULL
manuscript	NULL
in	NULL
preparation	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
effects	NULL
of	NULL
ys3*CaM-K	NULL
on	NULL
this	NULL
promoter	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
a	NULL
construct	NULL
of	NULL
IL-4	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
.	NULL

Similar	NULL
to	NULL
IL-2	NULL
,	NULL
transfection	NULL
with	NULL
ys*CaM-K	NULL
resulted	NULL
in	NULL
a	NULL
small	NULL
(	NULL
~40	NULL
%	NULL
)	NULL
but	NULL
reproducible	NULL
inhibition	NULL
of	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
IL-4	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
ionomycin	NULL
or	NULL
ACaM-AlI	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
ys	NULL
``	NULL
CaM-K	NULL
may	NULL
counteract	NULL
the	NULL
effects	NULL
of	NULL
calcineurin	NULL
(	NULL
and	NULL
probably	NULL
other	NULL
Ca*+-pathways	NULL
)	NULL
.	NULL

ys*CaM-K	NULL
Counteracts	NULL
the	NULL
Effects	NULL
of	NULL
ACaM-A1I	NULL
on	NULL
IL-2	NULL
Promoter	NULL
.	NULL

-	NULL
To	NULL
further	NULL
explore	NULL
the	NULL
interaction	NULL
between	NULL
calcineurin	NULL
and	NULL
CaM	NULL
kinase	NULL
,	NULL
we	NULL
cotransfected	NULL
Jurkat	NULL
cells	NULL
with	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
ACaM-AI	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
ys*CaM-K	NULL
.	NULL

In	NULL
cells	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
cotransfection	NULL
with	NULL
yg	NULL
``	NULL
CaM-K	NULL
completely	NULL
abolished	NULL
the	NULL
su-perinduction	NULL
of	NULL
IL-2	NULL
promoter	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
ACaM-AlI	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

Similar	NULL
to	NULL
its	NULL
effects	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
,	NULL
ya	NULL
``	NULL
*CaM-K	NULL
partially	NULL
downregulated	NULL
the	NULL
increase	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
NF-AT	NULL
construct	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
ACaM-AI	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
further	NULL
evidence	NULL
that	NULL
ys	NULL
``	NULL
may	NULL
counteract	NULL
the	NULL
effects	NULL
of	NULL
calcineurin	NULL
depen-dent-pathways	NULL
on	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

ys*CaM-K	NULL
Downregulates	NULL
the	NULL
Effects	NULL
of	NULL
PKC	NULL
on	NULL
Transactivation	NULL
of	NULL
AP-1	NULL
.	NULL

-	NULL
In	NULL
contrast	NULL
to	NULL
NF-AT	NULL
whereby	NULL
Ca**	NULL
is	NULL
essential	NULL
for	NULL
its	NULL
activation	NULL
,	NULL
stimulation	NULL
with	NULL
phorbol	NULL
esters	NULL
alone	NULL
is	NULL
sufficient	NULL
and	NULL
more	NULL
potent	NULL
than	NULL
ionomycin	NULL
to	NULL
induce	NULL
AP-1	NULL
activity	NULL
(	NULL
16	NULL
,	NULL
17	NULL
)	NULL
.	NULL

To	NULL
explore	NULL
the	NULL
interaction	NULL
of	NULL
CaM	NULL
kinase	NULL
1-4	NULL
cat	NULL
1100	NULL
#	NULL
y	NULL
5	NULL
Â°F	NULL
ion	NULL
.	NULL

(	NULL
-1	NULL
g	NULL
,	NULL
109	NULL
A10	NULL
.	NULL

+	NULL
E	NULL
a	NULL
9	NULL
g	NULL
200	NULL
Figure	NULL
.	NULL

3.	NULL
yB	NULL
``	NULL
CaM-K.	NULL
decreases	NULL
&	NULL
the	NULL
activity	NULL
of	NULL
IL-4	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
activation	NULL
with	NULL
ionomycin	NULL
or	NULL
ACaM-AI	NULL
.	NULL

Cells	NULL
cotransfected	NULL
with	NULL
15	NULL
ug	NULL
of	NULL
IL-4	NULL
-	NULL
CAT	NULL
(	NULL
which	NULL
contains	NULL
IL-4	NULL
pro-x	NULL
moter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
)	NULL
in	NULL
x	NULL
combination	NULL
with	NULL
J	NULL
and/or	NULL
ACaM-AI	NULL
(	NULL
7.5	NULL
ug	NULL
)	NULL
.	NULL

e	NULL
Brief	NULL
Definitive	NULL
Report	NULL
8	NULL
Figure	NULL
4.	NULL
ym	NULL
``	NULL
*CaM-K	NULL
counteracts	NULL
the	NULL
effects	NULL
of	NULL
ACaM-AI	NULL
on	NULL
IL-2	NULL
promoter	NULL
.	NULL

Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
IL-2	NULL
CAT	NULL
(	NULL
5	NULL
pg	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
ACaM-Al	NULL
and/or	NULL
ys	NULL
``	NULL
*CaM-K	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
RELATIVE	NULL
CAT	NULL
ACTIVITY	NULL
,	NULL
%	NULL
0	NULL
A	NULL
_	NULL
2D	NULL
PMA	NULL
.	NULL

Results	NULL
{	NULL
expressed	NULL
as	NULL
per-y	NULL
41k	NULL
St	NULL
,	NULL
centage	NULL
activity	NULL
observed	NULL
in	NULL
cells	NULL
-	NULL
$	NULL
f	NULL
Cie	NULL
transfected	NULL
with	NULL
vector	NULL
alone	NULL
)	NULL
v	NULL
__	NULL
@	NULL
Â®	NULL
Â®	NULL
were	NULL
normalized	NULL
to	NULL
the	NULL
activity	NULL
of	NULL
Â¢	NULL
pCMV.Gal	NULL
which	NULL
was	NULL
used	NULL
to	NULL
i	NULL
monitor	NULL
for	NULL
transfection	NULL
efficiency	NULL
Ã©	NULL
?	NULL

(	NULL
mean	NULL
#	NULL
SE	NULL
)	NULL
.	NULL

II	NULL
with	NULL
PKC-dependent	NULL
pathways	NULL
during	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
cotransfected	NULL
with	NULL
an	NULL
AP-1	NULL
construct	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
reporter	NULL
gene	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
with	NULL
constitutive	NULL
active	NULL
mutants	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
,	NULL
calcineurin	NULL
,	NULL
and	NULL
PKC	NULL
(	NULL
y3	NULL
``	NULL
*CaM-K	NULL
,	NULL
ACaM-AlI	NULL
,	NULL
and	NULL
respectively	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
cotransfection	NULL
with	NULL
APKC3	NULL
increased	NULL
the	NULL
baseline	NULL
activity	NULL
of	NULL
AP-1	NULL
by	NULL
approximately	NULL
six-fold	NULL
.	NULL

Stimulation	NULL
with	NULL
PMA	NULL
further	NULL
induced	NULL
the	NULL
activity	NULL
of	NULL
AP-1	NULL
.	NULL

Under	NULL
both	NULL
conditions	NULL
cotransfection	NULL
with	NULL
ys*CaM-K	NULL
downregulated	NULL
the	NULL
AP-1	NULL
activity	NULL
by	NULL
~60	NULL
%	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
ys	NULL
``	NULL
CaM-K	NULL
,	NULL
ACaM-AlI	NULL
also	NULL
downregulated	NULL
the	NULL
AP-1	NULL
activity	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
PMA	NULL
(	NULL
~50	NULL
%	NULL
inhibition	NULL
,	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
the	NULL
same	NULL
figure	NULL
,	NULL
the	NULL
downregulatory	NULL
effects	NULL
of	NULL
ACaM-AI	NULL
and	NULL
were	NULL
not	NULL
synergistic	NULL
.	NULL

These	NULL
data	NULL
suggest	NULL
that	NULL
under	NULL
certain	NULL
conditions	NULL
both	NULL
calcineurin	NULL
and	NULL
CaM	NULL
kinase	NULL
II	NULL
may	NULL
downregulate	NULL
PKC-dependent	NULL
transactivation	NULL
pathways	NULL
.	NULL

AP-1	NULL
CAT	NULL
Â®	NULL
iso	NULL
(	NULL
-	NULL
)	NULL
E	NULL
arma	NULL
(	NULL
+	NULL
)	NULL
>	NULL
5	NULL
100	NULL
<	NULL
4	NULL
i	NULL
U	NULL
L	NULL
-	NULL
50	NULL
ja	NULL
L	NULL
Â©	NULL
_	NULL
o	NULL
4	NULL
4	NULL
4	NULL
&	NULL
-	NULL
$	NULL
&	NULL
C	NULL
-N	NULL
4	NULL
cP	NULL
Y	NULL
*	NULL
%	NULL
&	NULL
~/	NULL
:	NULL
\	NULL
4g	NULL
4	NULL
Y	NULL
Figure	NULL
5.	NULL
.	NULL

ys	NULL
``	NULL
CaM-K	NULL
downregulates	NULL
the	NULL
transactivation	NULL
of	NULL
AP-1	NULL
in	NULL
response	NULL
to	NULL
cotransfection	NULL
with	NULL
and/or	NULL
stimulation	NULL
with	NULL
PMA	NULL
.	NULL

Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
plasmids	NULL
AP-1	NULL
CAT	NULL
(	NULL
5	NULL
ug	NULL
)	NULL
in	NULL
combination	NULL
with	NULL
ya	NULL
``	NULL
CaM-K	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
and/or	NULL
APKCG3	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
results	NULL
in	NULL
five	NULL
independent	NULL
experiments	NULL
.	NULL

1220	NULL
AP-1	NULL
CAT	NULL
a	NULL
%	NULL
Figure	NULL
6	NULL
.	NULL

Both	NULL
ya	NULL
``	NULL
CaM-K	NULL
and	NULL
ACaM-AI	NULL
downregulate	NULL
the	NULL
transactivation	NULL
of	NULL
AP-1	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
with	NULL
PMA	NULL
.	NULL

Cells	NULL
were	NULL
cotransfected	NULL
with	NULL
plasmids	NULL
APA	NULL
CAT	NULL
(	NULL
5	NULL
pg	NULL
)	NULL
,	NULL
ys*CaM-K	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
and	NULL
ACaM-AI	NULL
(	NULL
10	NULL
ug	NULL
)	NULL
_E	NULL
{	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
)	NULL
,	NULL
and	NULL
Ã©	NULL
}	NULL
-	NULL
stimulated	NULL
with	NULL
PMA	NULL
.	NULL

Results	NULL
P	NULL
{	NULL
expressed	NULL
as	NULL
a	NULL
percentage	NULL
activity	NULL
C	NULL
observed	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
Â¢	NULL
the	NULL
pSRa	NULL
vector	NULL
alone	NULL
}	NULL
were	NULL
F	NULL
normalized	NULL
to	NULL
the	NULL
activity	NULL
of	NULL
G	NULL
pCMV.Gal	NULL
(	NULL
mean	NULL
+	NULL
SB	NULL
)	NULL
.	NULL

Ss	NULL
Sas	NULL
S	NULL
S	NULL
m	NULL
o	NULL
so	NULL
RELATIVE	NULL
CAT	NULL
ACTIVITY	NULL
,	NULL
%	NULL
3	NULL
]	NULL
s	NULL
S5	NULL
a	NULL
Bos	NULL
Z	NULL
Discussion	NULL
In	NULL
this	NULL
study	NULL
we	NULL
have	NULL
presented	NULL
evidence	NULL
that	NULL
CaM	NULL
kinase	NULL
II	NULL
may	NULL
downregulate	NULL
Ca*+-	NULL
and	NULL
PKC-dependent	NULL
transactivating	NULL
pathways	NULL
for	NULL
cytokine	NULL
gene	NULL
transcription	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
seems	NULL
to	NULL
be	NULL
specific	NULL
since	NULL
CaM	NULL
kinase	NULL
II	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
unrelated	NULL
promoter	NULL
pCMV.Gal	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
double	NULL
mutant	NULL
(	NULL
inactive/constitutive	NULL
)	NULL
ysCaM-K	NULL
does	NULL
not	NULL
affect	NULL
the	NULL
IL-2	NULL
promoter	NULL
activity	NULL
,	NULL
suggesting	NULL
that	NULL
inhibition	NULL
of	NULL
gene	NULL
transcription	NULL
requires	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
catalytically	NULL
active	NULL
domain	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
and	NULL
it	NULL
is	NULL
not	NULL
due	NULL
to	NULL
the	NULL
competing	NULL
effects	NULL
of	NULL
the	NULL
vectors	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
.	NULL

These	NULL
results	NULL
provide	NULL
a	NULL
molecular	NULL
basis	NULL
for	NULL
the	NULL
previously	NULL
reported	NULL
negative	NULL
effects	NULL
of	NULL
the	NULL
Ca**-pathway	NULL
on	NULL
T	NULL
cells	NULL
,	NULL
such	NULL
as	NULL
negative	NULL
selection	NULL
and	NULL
anergy	NULL
(	NULL
18-20	NULL
)	NULL
.	NULL

IL-2	NULL
is	NULL
one	NULL
of	NULL
the	NULL
major	NULL
growth	NULL
factors	NULL
for	NULL
the	NULL
cells	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
.	NULL

Inadequate	NULL
production	NULL
of	NULL
IL-2	NULL
has	NULL
significant	NULL
consequences	NULL
for	NULL
the	NULL
T	NULL
cells	NULL
and	NULL
may	NULL
result	NULL
in	NULL
anergy	NULL
and	NULL
tolerance	NULL
.	NULL

Exogenous	NULL
II-2	NULL
or	NULL
costimulation	NULL
via	NULL
the	NULL
CD28	NULL
pathway	NULL
may	NULL
reverse	NULL
these	NULL
states	NULL
suggesting	NULL
that	NULL
the	NULL
total	NULL
amount	NULL
of	NULL
IL-2	NULL
produced	NULL
in	NULL
an	NULL
immune	NULL
response	NULL
plays	NULL
a	NULL
critical	NULL
role	NULL
in	NULL
determining	NULL
the	NULL
extent	NULL
of	NULL
the	NULL
anergy	NULL
(	NULL
20	NULL
,	NULL
21	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
playing	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
physiological	NULL
immune	NULL
responses	NULL
against	NULL
foreign	NULL
antigens	NULL
IL-2	NULL
may	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
autoimmune	NULL
phenomena	NULL
.	NULL

A	NULL
stringent	NULL
control	NULL
of	NULL
the	NULL
production	NULL
of	NULL
IL-2	NULL
is	NULL
therefore	NULL
required	NULL
to	NULL
avoid	NULL
excess	NULL
production	NULL
which	NULL
may	NULL
lead	NULL
to	NULL
breaking	NULL
of	NULL
tolerance	NULL
and	NULL
autoimmune	NULL
phenomena	NULL
.	NULL

Work	NULL
from	NULL
several	NULL
laboratories	NULL
has	NULL
associated	NULL
the	NULL
lack	NULL
of	NULL
IL-2	NULL
production	NULL
in	NULL
anergic	NULL
states	NULL
to	NULL
defects	NULL
in	NULL
the	NULL
transactivation	NULL
of	NULL
nuclear	NULL
factors	NULL
,	NULL
AP-1	NULL
(	NULL
22	NULL
)	NULL
,	NULL
NF-AT	NULL
,	NULL
and	NULL
NF-KB	NULL
(	NULL
23	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
activation	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
may	NULL
provide	NULL
an	NULL
additional	NULL
regulatory	NULL
mechanism	NULL
for	NULL
the	NULL
fine	NULL
tuning	NULL
of	NULL
IL-2	NULL
production	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
the	NULL
downregulation	NULL
of	NULL
these	NULL
transactivating	NULL
pathways	NULL
may	NULL
be	NULL
due	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
to	NULL
activation	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
.	NULL

Although	NULL
in	NULL
these	NULL
experiments	NULL
CaM	NULL
kinase	NULL
II	NULL
only	NULL
partially	NULL
inhibited	NULL
IL-2	NULL
transcription	NULL
,	NULL
this	NULL
may	NULL
be	NULL
sufficient	NULL
to	NULL
result	NULL
in	NULL
autocrine	NULL
rather	NULL
than	NULL
paracrine	NULL
levels	NULL
of	NULL
IL-2	NULL
production	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
degree	NULL
of	NULL
inhibition	NULL
may	NULL
differ	NULL
among	NULL
different	NULL
types	NULL
or	NULL
clones	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

CaM	NULL
Kinase	NULL
II	NULL
and	NULL
Cytokine	NULL
Gene	NULL
Transcription	NULL
In	NULL
the	NULL
murine	NULL
system	NULL
of	NULL
T	NULL
cell	NULL
anergy	NULL
,	NULL
costimulation	NULL
of	NULL
T	NULL
cells	NULL
through	NULL
the	NULL
CD28	NULL
pathway	NULL
augments	NULL
IL-2	NULL
production	NULL
from	NULL
autocrine	NULL
to	NULL
paracrine	NULL
levels	NULL
and	NULL
prevents	NULL
induction	NULL
of	NULL
anergy	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Although	NULL
increases	NULL
in	NULL
[	NULL
Ca	NULL
#	NULL
+	NULL
]	NULL
;	NULL
during	NULL
activation	NULL
through	NULL
TCR	NULL
will	NULL
activate	NULL
both	NULL
calcineurin	NULL
(	NULL
which	NULL
augments	NULL
IL-2	NULL
production	NULL
)	NULL
and	NULL
CaM	NULL
kinase	NULL
II	NULL
(	NULL
which	NULL
decreases	NULL
it	NULL
)	NULL
,	NULL
it	NULL
is	NULL
conceivable	NULL
that	NULL
additional	NULL
accessory	NULL
stimuli	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
stimulation	NULL
via	NULL
CD2	NULL
,	NULL
CD5	NULL
,	NULL
or	NULL
CD28	NULL
)	NULL
may	NULL
shift	NULL
the	NULL
balance	NULL
towards	NULL
one	NULL
or	NULL
the	NULL
other	NULL
of	NULL
these	NULL
enzymes	NULL
.	NULL

Downregulation	NULL
of	NULL
IL-4	NULL
production	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
is	NULL
also	NULL
of	NULL
interest	NULL
.	NULL

IL-4	NULL
is	NULL
the	NULL
other	NULL
major	NULL
T	NULL
cell	NULL
growth	NULL
factor	NULL
and	NULL
is	NULL
essential	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
humoral	NULL
immune	NULL
re-sponses	NULL
.	NULL

Anergic	NULL
T	NULL
cells	NULL
lose	NULL
their	NULL
responsiveness	NULL
to	NULL
IL-4	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Decreased	NULL
production	NULL
of	NULL
IL-4	NULL
by	NULL
CaM	NULL
kinase	NULL
II	NULL
may	NULL
be	NULL
an	NULL
additional	NULL
proximal	NULL
mechanism	NULL
to	NULL
prevent	NULL
proliferative	NULL
response	NULL
by	NULL
these	NULL
cells	NULL
.	NULL

This	NULL
study	NULL
has	NULL
presented	NULL
preliminary	NULL
data	NULL
on	NULL
cross-talk	NULL
between	NULL
the	NULL
CaM	NULL
kinase	NULL
II	NULL
and	NULL
calcineurin	NULL
signaling	NULL
systems	NULL
.	NULL

During	NULL
T	NULL
cell	NULL
activation	NULL
the	NULL
partial	NULL
inhibition	NULL
of	NULL
IL-2	NULL
or	NULL
IL-4	NULL
promoter	NULL
activity	NULL
by	NULL
CaM	NULL
kinase	NULL
II	NULL
suggests	NULL
that	NULL
their	NULL
effects	NULL
may	NULL
be	NULL
exerted	NULL
at	NULL
more	NULL
distal	NULL
sites	NULL
in	NULL
the	NULL
calcineurin	NULL
regulated	NULL
pathways	NULL
.	NULL

Calcineurin	NULL
is	NULL
known	NULL
to	NULL
activate	NULL
several	NULL
dis	NULL
crete	NULL
transactivating	NULL
pathways	NULL
including	NULL
NF-AT	NULL
,	NULL
Oct-1/OAP	NULL
,	NULL
and	NULL
NF-KB	NULL
and	NULL
to	NULL
downregulate	NULL
the	NULL
activity	NULL
of	NULL
AP-1	NULL
(	NULL
7-10	NULL
)	NULL
.	NULL

Hashimoto	NULL
et	NULL
al	NULL
.	NULL

(	NULL
24	NULL
)	NULL
have	NULL
shown	NULL
that	NULL
calcineurin	NULL
is	NULL
phos-phorylated	NULL
by	NULL
the	NULL
autophosphorylated	NULL
form	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
.	NULL

Whether	NULL
these	NULL
in	NULL
vitro	NULL
data	NULL
have	NULL
any	NULL
relevance	NULL
to	NULL
explaining	NULL
the	NULL
attenuating	NULL
effects	NULL
of	NULL
CaM	NULL
kinase	NULL
II	NULL
on	NULL
calcineurin	NULL
in	NULL
vivo	NULL
can	NULL
not	NULL
be	NULL
addressed	NULL
by	NULL
these	NULL
studies	NULL
.	NULL

Whereas	NULL
it	NULL
is	NULL
well	NULL
established	NULL
that	NULL
PKC	NULL
may	NULL
exhibit	NULL
both	NULL
negative	NULL
and	NULL
positive	NULL
cross-talk	NULL
with	NULL
CaM	NULL
kinase	NULL
II	NULL
(	NULL
25	NULL
)	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
CaM	NULL
kinase	NULL
on	NULL
PKC	NULL
are	NULL
less	NULL
well	NULL
characterized	NULL
.	NULL

Our	NULL
data	NULL
provide	NULL
for	NULL
the	NULL
first	NULL
time	NULL
evidence	NULL
that	NULL
CaM	NULL
kinase	NULL
II	NULL
may	NULL
downregulate	NULL
PKC-dependent	NULL
pathways	NULL
for	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Once	NULL
more	NULL
the	NULL
partial	NULL
inactivation	NULL
of	NULL
the	NULL
PKC	NULL
mediated	NULL
AP-1	NULL
induction	NULL
suggests	NULL
that	NULL
CaM	NULL
kinase	NULL
II	NULL
more	NULL
likely	NULL
affects	NULL
distal	NULL
sites	NULL
in	NULL
the	NULL
PKC	NULL
mediated	NULL
pathway	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
data	NULL
have	NULL
identified	NULL
CaM	NULL
kinase	NULL
II	NULL
as	NULL
a	NULL
potential	NULL
candidate	NULL
for	NULL
some	NULL
of	NULL
the	NULL
negative	NULL
effects	NULL
of	NULL
the	NULL
Ca**-pathway	NULL
on	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Furthermore	NULL
,	NULL
these	NULL
data	NULL
provide	NULL
indirect	NULL
evidence	NULL
for	NULL
cross-talk	NULL
between	NULL
the	NULL
calcium	NULL
and	NULL
the	NULL
PKC	NULL
pathways	NULL
during	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Additional	NULL
studies	NULL
should	NULL
further	NULL
delineate	NULL
this	NULL
interaction	NULL
and	NULL
determine	NULL
its	NULL
importance	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
authors	NULL
thank	NULL
Dr.	NULL
H.	NULL
Schulman	NULL
for	NULL
plasmid	NULL
y2*CaM-K	NULL
and	NULL
helpful	NULL
discussions	NULL
;	NULL
Dr.	NULL
J.	NULL
E.	NULL
Balow	NULL
for	NULL
his	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
and	NULL
useful	NULL
suggestions	NULL
;	NULL
Dr.	NULL
M.	NULL
A.	NULL
Valentine	NULL
for	NULL
her	NULL
help	NULL
with	NULL
the	NULL
CaM	NULL
kinase	NULL
II	NULL
assays	NULL
;	NULL
Dr.	NULL
S.	NULL
Matsushita	NULL
for	NULL
technical	NULL
advice	NULL
;	NULL
and	NULL
L.	NULL
A.	NULL
Miller	NULL
and	NULL
A.	NULL
S.	NULL
Lerner	NULL
for	NULL
preparation	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
N.	NULL
Hama	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bldg	NULL
.	NULL

10	NULL
,	NULL
Rm	NULL
.	NULL

3N112	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
20892-1268	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
30	NULL
August	NULL
1994	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
9	NULL
December	NULL
1994	NULL
.	NULL

Note	NULL
added	NULL
in	NULL
proof	NULL
:	NULL
Work	NULL
published	NULL
by	NULL
Ngheim	NULL
et	NULL
al	NULL
.	NULL

(	NULL
26	NULL
)	NULL
after	NULL
the	NULL
original	NULL
submission	NULL
of	NULL
this	NULL
manuscript	NULL
corroborates	NULL
our	NULL
findings	NULL
for	NULL
attenuation	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
by	NULL
CaM	NULL
kinase	NULL
II	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Ullman	NULL
,	NULL
K.S	NULL
.	NULL

,	NULL
J.P.	NULL
Northrop	NULL
,	NULL
C.L	NULL
.	NULL

Verweij	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1990	NULL
.	NULL

Transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
receptor	NULL
to	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
cell	NULL
proliferation	NULL
and	NULL
immune	NULL
function	NULL
:	NULL
the	NULL
missing	NULL
link	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

8:421-452	NULL
.	NULL

2	NULL
.	NULL

Fraser	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
B.A	NULL
.	NULL

Irving	NULL
,	NULL
G.R	NULL
.	NULL

Crabtree	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
interleukin-2	NULL
gene	NULL
enhancer	NULL
activity	NULL
by	NULL
the	NULL
T-cell	NULL
accessory	NULL
molecule	NULL
CD28	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

251:313-316	NULL
.	NULL

3	NULL
.	NULL

Hanson	NULL
,	NULL
PI	NULL
.	NULL

,	NULL
and	NULL
H.	NULL
Schulman	NULL
.	NULL

1992	NULL
.	NULL

Neuronal	NULL
Ca	NULL
#	NULL
*/cal-modulin-dependent	NULL
protein	NULL
kinases	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

61	NULL
:	NULL
559-601	NULL
.	NULL

4	NULL
.	NULL

Edman	NULL
,	NULL
C.F	NULL
.	NULL

,	NULL
and	NULL
H.	NULL
Schulman	NULL
.	NULL

1994	NULL
.	NULL

Identification	NULL
and	NULL
characterization	NULL
of	NULL
kinase	NULL
and	NULL
dc-CaM	NULL
kinase	NULL
from	NULL
rat	NULL
heart	NULL
,	NULL
two	NULL
new	NULL
multifunctional	NULL
Ca**	NULL
/calmodulin-dependent	NULL
protein	NULL
kinase	NULL
isoforms	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
.	NULL

1221:89-101	NULL
.	NULL

5	NULL
.	NULL

Nghiem	NULL
,	NULL
P.	NULL
,	NULL
SM	NULL
.	NULL

Saati	NULL
,	NULL
C.L	NULL
.	NULL

Martens	NULL
,	NULL
P.	NULL
Gardner	NULL
,	NULL
and	NULL
H.	NULL
Schulman	NULL
.	NULL

1993	NULL
.	NULL

Cloning	NULL
and	NULL
analysis	NULL
of	NULL
two	NULL
new	NULL
isoforms	NULL
of	NULL
multifunctional	NULL
Ca	NULL
#	NULL
*	NULL
/calmodulin-dependent	NULL
protein	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

268:5471-5479	NULL
.	NULL

6	NULL
.	NULL

Kapiloff	NULL
,	NULL
M.S	NULL
,	NULL
J.M	NULL
.	NULL

Mathis	NULL
,	NULL
C.A	NULL
.	NULL

Nelson	NULL
,	NULL
C.R	NULL
.	NULL

Lin	NULL
,	NULL
and	NULL
MG.	NULL
1221	NULL
Hama	NULL
et	NULL
al	NULL
.	NULL

Rosenfeld	NULL
.	NULL

1991	NULL
.	NULL

Calcium/calmodulin-dependent	NULL
protein	NULL
kinase	NULL
mediates	NULL
a	NULL
pathway	NULL
for	NULL
transcriptional	NULL
regulation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

88:3710-3714	NULL
.	NULL

7	NULL
.	NULL

O'Keefe	NULL
,	NULL
S.J	NULL
.	NULL

,	NULL
J.	NULL
Tamura	NULL
,	NULL
RL	NULL
.	NULL

Kincaid	NULL
,	NULL
M.J.	NULL
Tocci	NULL
,	NULL
and	NULL
E.A	NULL
.	NULL

O'Neil	NULL
.	NULL

1992	NULL
.	NULL

FK-506-	NULL
and	NULL
CsA-sensitive	NULL
activation	NULL
of	NULL
the	NULL
interleukin-2	NULL
promoter	NULL
by	NULL
calcineurin	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

357	NULL
:	NULL
692-694	NULL
.	NULL

8	NULL
.	NULL

Clipstone	NULL
,	NULL
N.A	NULL
.	NULL

,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
calcineurin	NULL
as	NULL
a	NULL
key	NULL
signaling	NULL
enzyme	NULL
in	NULL
T-lymphocyte	NULL
activation	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

357:695-697	NULL
.	NULL

9	NULL
.	NULL

Kubo	NULL
,	NULL
M.	NULL
,	NULL
RL	NULL
.	NULL

Kincaid	NULL
,	NULL
D.R	NULL
.	NULL

Webb	NULL
,	NULL
and	NULL
J.T	NULL
.	NULL

Ransom	NULL
.	NULL

1994	NULL
.	NULL

The	NULL
Ca**	NULL
/calmodulin-activated	NULL
,	NULL
phosphoprotein	NULL
phosphatase	NULL
calcineurin	NULL
is	NULL
sufficient	NULL
for	NULL
positive	NULL
transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
mouse	NULL
IL-4	NULL
gene	NULL
.	NULL

Int	NULL
.	NULL

Immunol	NULL
.	NULL

6:179-188	NULL
.	NULL

10	NULL
.	NULL

Frantz	NULL
,	NULL
B.	NULL
,	NULL
E.C	NULL
.	NULL

Nordby	NULL
,	NULL
G.	NULL
Bren	NULL
,	NULL
N.	NULL
Steffan	NULL
,	NULL
CV	NULL
.	NULL

Paya	NULL
,	NULL
RL	NULL
.	NULL

Kincaid	NULL
,	NULL
M.J.	NULL
Tocci	NULL
,	NULL
S.J	NULL
.	NULL

O'Keefe	NULL
,	NULL
and	NULL
E.A	NULL
.	NULL

O'Neil	NULL
.	NULL

1994	NULL
.	NULL

Calcineurin	NULL
acts	NULL
in	NULL
synergy	NULL
with	NULL
PMA	NULL
to	NULL
inactivate	NULL
IxB/MAD3	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
NF-kB	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

13:861-870	NULL
.	NULL

11	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
M.A	NULL
.	NULL

Valentine	NULL
,	NULL
and	NULL
DIT	NULL
.	NULL

Boumpas	NULL
.	NULL

1993	NULL
.	NULL

Brief	NULL
Definitive	NULL
Report	NULL
12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

Glucocorticoids	NULL
inhibit	NULL
calcium	NULL
but	NULL
not	NULL
protein	NULL
kinase	NULL
C	NULL
dependent	NULL
pathways	NULL
for	NULL
T-cell	NULL
activation	NULL
.	NULL

Arthritis	NULL
Rhuem	NULL
.	NULL

36	NULL
:	NULL
$	NULL
113	NULL
.	NULL

(	NULL
Abstr	NULL
.	NULL
)	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
M.	NULL
Imagawa	NULL
,	NULL
R.	NULL
Chiu	NULL
,	NULL
B.	NULL
Stein	NULL
,	NULL
R.J.	NULL
Imbra	NULL
,	NULL
H.J	NULL
.	NULL

Rahmsdorf	NULL
,	NULL
C.	NULL
Jonat	NULL
,	NULL
P.	NULL
Herrlich	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1987	NULL
.	NULL

Phorbol	NULL
ester-inducible	NULL
genes	NULL
contain	NULL
a	NULL
common	NULL
cis	NULL
element	NULL
recognized	NULL
by	NULL
a	NULL
TPA-modulated	NULL
trans-acting	NULL
factor	NULL
.	NULL

Cell	NULL
.	NULL

49:729-739	NULL
.	NULL

Muramatsu	NULL
,	NULL
M.-A	NULL
.	NULL

,	NULL
K.	NULL
Kaibuchi	NULL
,	NULL
and	NULL
K.-I	NULL
.	NULL

Arai	NULL
.	NULL

1989	NULL
.	NULL

A	NULL
protein	NULL
kinase	NULL
C	NULL
cDNA	NULL
without	NULL
the	NULL
regulatory	NULL
domain	NULL
is	NULL
active	NULL
after	NULL
transfection	NULL
in	NULL
vivo	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
phorbol	NULL
ester	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

9:831-836	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
R.L	NULL
.	NULL

Kincaid	NULL
,	NULL
and	NULL
D.T	NULL
.	NULL

Boumpas	NULL
.	NULL

1993	NULL
.	NULL

Pros-taglandin	NULL
E	NULL
;	NULL
and	NULL
other	NULL
cyclic	NULL
AMP	NULL
elevating	NULL
agents	NULL
inhibit	NULL
interleukin	NULL
2	NULL
gene	NULL
transcription	NULL
by	NULL
counteracting	NULL
calcineurin-dependent	NULL
pathways	NULL
.	NULL

J.	NULL
Exp	NULL
Med	NULL
.	NULL

178:1813-1817	NULL
.	NULL

Tamura	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Yanagida	NULL
,	NULL
and	NULL
H.	NULL
Nariuchi	NULL
.	NULL

1993	NULL
.	NULL

Difference	NULL
in	NULL
signal	NULL
transduction	NULL
pathway	NULL
for	NULL
IL-2	NULL
and	NULL
IL-4	NULL
production	NULL
in	NULL
T	NULL
helper	NULL
1	NULL
and	NULL
T	NULL
helper	NULL
2	NULL
cell	NULL
clones	NULL
in	NULL
reponse	NULL
to	NULL
anti-CD3	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:6051-6061	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
A.	NULL
Raptis	NULL
,	NULL
S.S.	NULL
Ahuja	NULL
,	NULL
SM	NULL
.	NULL

Najjar	NULL
,	NULL
and	NULL
DT	NULL
.	NULL

Boumpas	NULL
.	NULL

1993	NULL
.	NULL

Negative	NULL
transcriptional	NULL
regulation	NULL
of	NULL
human	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
gene	NULL
by	NULL
glucocorticoids	NULL
through	NULL
interference	NULL
with	NULL
nuclear	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

91:1481-1489	NULL
.	NULL

Ullman	NULL
,	NULL
K.S	NULL
$	NULL
.	NULL

,	NULL
J.P.	NULL
Northrop	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
and	NULL
G.R	NULL
.	NULL

Crabtree	NULL
.	NULL

1993	NULL
.	NULL

Jun	NULL
family	NULL
members	NULL
are	NULL
controlled	NULL
by	NULL
a	NULL
calcium-regulated	NULL
,	NULL
cyclosporin	NULL
A-sensitive	NULL
signaling	NULL
pathway	NULL
in	NULL
activated	NULL
T	NULL
lym-phocytes	NULL
.	NULL

Genes	NULL
&	NULL
Dev	NULL
.	NULL

7:188-196	NULL
.	NULL

Nakayama	NULL
,	NULL
T.	NULL
,	NULL
Y.	NULL
Ueda	NULL
,	NULL
H.	NULL
Yamada	NULL
,	NULL
EW	NULL
.	NULL

Shores	NULL
,	NULL
A	NULL
.	NULL

Singer	NULL
,	NULL
1222	NULL
19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26.	NULL
and	NULL
C.H	NULL
.	NULL

June	NULL
.	NULL

1992	NULL
.	NULL

In	NULL
vivo	NULL
calcium	NULL
elevations	NULL
in	NULL
thymocytes	NULL
with	NULL
cell	NULL
receptors	NULL
that	NULL
are	NULL
specific	NULL
for	NULL
self	NULL
ligand	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

257:96-99	NULL
.	NULL

Siegel	NULL
,	NULL
J.N	NULL
.	NULL

,	NULL
and	NULL
C.H	NULL
.	NULL

June	NULL
.	NULL

1993	NULL
.	NULL

Signal	NULL
transduction	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
and	NULL
tolerance	NULL
.	NULL

In	NULL
New	NULL
Concepts	NULL
in	NULL
Immuno-deficiency	NULL
Dieases	NULL
.	NULL

S.	NULL
Gupta	NULL
,	NULL
and	NULL
C.	NULL
Griscelli	NULL
,	NULL
editors	NULL
.	NULL

John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Chichester	NULL
,	NULL
NY	NULL
.	NULL

85-129	NULL
.	NULL

Schwartz	NULL
,	NULL
R.H.	NULL
1992	NULL
.	NULL

Costimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
:	NULL
The	NULL
role	NULL
of	NULL
CD28	NULL
,	NULL
CTLA-4	NULL
,	NULL
and	NULL
B7/BB1	NULL
in	NULL
interleukin-2	NULL
production	NULL
and	NULL
immunotherapy	NULL
.	NULL

Cell	NULL
.	NULL

71:1065-1068	NULL
.	NULL

Harding	NULL
,	NULL
FA	NULL
.	NULL

,	NULL
J.G	NULL
.	NULL

McArthur	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

Gross	NULL
,	NULL
D.H.	NULL
Raulet	NULL
,	NULL
and	NULL
J.P.	NULL
Allison	NULL
.	NULL

1992	NULL
.	NULL

CD28-mediated	NULL
signaling	NULL
co-stimulates	NULL
murine	NULL
T	NULL
cells	NULL
and	NULL
prevents	NULL
induction	NULL
of	NULL
anergy	NULL
in	NULL
T-cell	NULL
clones	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

356:607-609	NULL
.	NULL

Kang	NULL
,	NULL
S.-M.	NULL
,	NULL
B.	NULL
Beverly	NULL
,	NULL
A.-C.	NULL
Tran	NULL
,	NULL
K.	NULL
Brorson	NULL
,	NULL
R.H.	NULL
Schwartz	NULL
,	NULL
and	NULL
M.J.	NULL
Lenardo	NULL
.	NULL

1992	NULL
.	NULL

Transactivation	NULL
by	NULL
AP-1	NULL
is	NULL
a	NULL
molecular	NULL
target	NULL
of	NULL
T	NULL
cell	NULL
clonal	NULL
anergy	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

257:1134-1138	NULL
.	NULL

Go	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
J.	NULL
Miller	NULL
.	NULL

1992	NULL
.	NULL

Differential	NULL
induction	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
during	NULL
anergy	NULL
induction	NULL
and	NULL
restimulation	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1327-1336	NULL
.	NULL

Hashimoto	NULL
,	NULL
Y.	NULL
,	NULL
and	NULL
T.R	NULL
.	NULL

Soderling	NULL
.	NULL

1989	NULL
.	NULL

Regulation	NULL
of	NULL
calcineurin	NULL
by	NULL
phosphorylation	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

264:16524-16529	NULL
.	NULL

MacNicol	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
H.	NULL
Schulman	NULL
.	NULL

1992	NULL
.	NULL

Cross-talk	NULL
between	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
multifunctional	NULL
Ca	NULL
#	NULL
*	NULL
/calmodulin-dependent	NULL
protein	NULL
kinase	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

267:12197-12201	NULL
.	NULL

Nghiem	NULL
,	NULL
P.	NULL
,	NULL
T.	NULL
Ollick	NULL
,	NULL
P.	NULL
Gardner	NULL
,	NULL
and	NULL
H.	NULL
Schulman	NULL
.	NULL

1994	NULL
.	NULL

Interleukin-2	NULL
transcriptional	NULL
block	NULL
by	NULL
multifunctional	NULL
Ca*+	NULL
/	NULL
calmodulin	NULL
kinase	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

371:347-350	NULL
.	NULL

CaM	NULL
Kinase	NULL
II	NULL
and	NULL
Cytokine	NULL
Gene	NULL
Transcription	NULL

